These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 25921702)

  • 1. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
    Ahmed MF; Belal A
    Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
    Belal A
    Bioorg Chem; 2015 Apr; 59():124-9. PubMed ID: 25748126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer activity evaluation of some novel pyrrolo[1,2-a]azepine derivatives.
    Belal A
    Arch Pharm (Weinheim); 2014 Jul; 347(7):515-22. PubMed ID: 24729464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of quinazolinone tagged acridones as cytotoxic agents and their effects on EGFR tyrosine kinase.
    Babu YR; Bhagavanraju M; Reddy GD; Peters GJ; Prasad VV
    Arch Pharm (Weinheim); 2014 Sep; 347(9):624-34. PubMed ID: 24866341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinazolin-4(3
    Mirgany TO; Abdalla AN; Arifuzzaman M; Motiur Rahman AFM; Al-Salem HS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2055-2067. PubMed ID: 34551654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel quinazolin-4(3H)-one/Schiff base hybrids as antiproliferative and phosphodiesterase 4 inhibitors: design, synthesis, and docking studies.
    Abdel-Rahman HM; Abdel-Aziz M; Canzoneri JC; Gary BD; Piazza GA
    Arch Pharm (Weinheim); 2014 Sep; 347(9):650-7. PubMed ID: 24985336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and antitumor activity of novel pyrazolo[3,4-d]pyrimidine derivatives as EGFR-TK inhibitors.
    Abdelgawad MA; Bakr RB; Alkhoja OA; Mohamed WR
    Bioorg Chem; 2016 Jun; 66():88-96. PubMed ID: 27043178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
    Ammar YA; Sh El-Sharief AM; Belal A; Abbas SY; Mohamed YA; Mehany ABM; Ragab A
    Eur J Med Chem; 2018 Aug; 156():918-932. PubMed ID: 30096580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and
    Le Y; Gan Y; Fu Y; Liu J; Li W; Zou X; Zhou Z; Wang Z; Ouyang G; Yan L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):555-564. PubMed ID: 31967481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
    El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of a novel series of 6,8-dibromo-4(3H)quinazolinone derivatives as anticancer agents.
    Ahmed MF; Youns M
    Arch Pharm (Weinheim); 2013 Aug; 346(8):610-7. PubMed ID: 23873839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.
    Zhang Y; Wang Q; Li L; Le Y; Liu L; Yang J; Li Y; Bao G; Yan L
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1205-1216. PubMed ID: 34074193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Antiproliferative Activity of Quinazolin-4-One/Chalcone Hybrids
    Hisham M; Hassan HA; Gomaa HAM; Youssif BGM; Hayalah AM; Abdel-Aziz M
    Anticancer Agents Med Chem; 2023; 23(17):1932-1943. PubMed ID: 37497685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
    Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
    Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, In Silico and In Vitro Assessment of New Quinazolinones as Anticancer Agents via Potential AKT Inhibition.
    Noser AA; El-Naggar M; Donia T; Abdelmonsef AH
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33080996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
    Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors.
    El-Helby AA; Sakr H; Eissa IH; Abulkhair H; Al-Karmalawy AA; El-Adl K
    Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900113. PubMed ID: 31448458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.